RxSight

RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. It also commercializes adjustable intraocular lens (IOL) that is customized after cataract surgery. The company was founded by Robert Grubbs and Daniel Schwartz on March 5, 1997 and is headquartered in Aliso Viejo, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

RxSight posts stellar Q4 results, eyes strong growth in 2023

RxSight's Q4 2022 performance reflects robust revenue growth, improved gross margin, and strategic financial management. The company's focus on expanding LDD installations and LAL sales sets a positive trajectory for future growth.
While challenges such as net losses and operating expenses persist, RxSight's strong cash position and revenue guidance for 2023 indicate resilience and potential for sustained growth. Leveraging opportunities in market expansion and product innovation will be key for RxSight's future success.

RxSight reports stellar Q1 revenue growth, eyes profitability challenges

RxSight demonstrated robust revenue growth and a strong cash position in Q1 2023, while facing challenges with profitability and escalating operating expenses. The company's increased revenue guidance and positive market feedback present opportunities for future growth through product adoption and market expansion.

RxSight reports stellar Q2 results, raises guidance amid strategic focus

RxSight's Q2 2023 performance reflects robust revenue growth and margin improvement, supported by strong LAL sales. While challenges like net losses persist, the company's strategic focus on technology and market growth presents promising opportunities for future success.

RxSight reports stellar Q3 results, eyes profitability and product expansion

RxSight's Q3 performance reflects robust revenue growth, driven by strong LAL sales and operational efficiency improvements, positioning the company for future success.
With a focus on innovation and product efficacy, RxSight's strategic strengths lie in their ability to meet market demand and drive revenue through expanded offerings.
While challenges in managing expenses and sustaining growth persist, RxSight's financial strength and market opportunities signal a promising outlook for profitability and value creation.

RxSight reports strong revenue growth driven by LAL sales

RxSight's Q4 2023 performance showcased robust revenue growth driven by LAL sales, despite increased operating expenses and a net loss.
The company's strong cash position, debt-free status, and focus on innovation position it well for future revenue growth and market expansion.
Challenges include managing expenses, navigating complex international markets, and optimizing product mix for sustained profitability.
Opportunities lie in European market expansion, investor engagement, and leveraging technology to drive adoption and revenue growth.

RxSight reports robust Q1 revenue growth, faces expense challenges

RxSight's Q1 2024 performance reflects strong revenue growth and improved gross margin, yet challenges persist with increasing expenses and net loss.
The company's focus on LAL technology, guidance increase, and market expansion efforts present opportunities for future growth and market penetration.
To address challenges, RxSight needs to balance cost management with innovation and capitalize on opportunities in adoption trends and international markets.

RxSight reports robust Q2 earnings, eyes international expansion for growth

RxSight's Q2 performance reflects strong revenue growth, improved margins, and strategic investments in growth areas.
While facing rising expenses, RxSight's focus on premium products, international expansion, and innovation positions it for future success.
Challenges in cost management and market dynamics require careful navigation, but opportunities in product expansion and market penetration are promising.
Overall, RxSight's financial outlook remains positive, supported by a strong cash position and a clear growth strategy.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. It also commercializes adjustable intraocular lens (IOL) that is customized after cataract surgery. The company was founded on March 5, 1997 and is headquartered in Aliso Viejo, CA.

ALISO VIEJO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming 34th Annual Oppenheimer Healthcare Conference.

RxSight, Inc. to Participate in the 34th Annual Oppenheimer Healthcare Conference

RxSight, Inc. (RXST) Q4 2023 Earnings Call Transcript

ALISO VIEJO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months and full year ended December 31, 2023.

RxSight, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results

ALISO VIEJO, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) - RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the fourth quarter and full year 2023 after the market close on Wednesday, February 28, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

RxSight, Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024

Green Brick Partners

Remitly Global

Steve Symington is a long-time contributor to The Motley Fool. Over the years, he's written more than 8,000 articles for the publication.

3 Stocks to Buy BEFORE They Become Household Names

RxSight, Inc. (RXST) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, RXST crossed above the 20-day moving average, suggesting a short-term bullish trend.

RxSight, Inc. (RXST) Just Overtook the 20-Day Moving Average

ALISO VIEJO, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2023 and provided full-year 2024 guidance.

RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Financial and Operational Results and 2024 Guidance

ALISO VIEJO, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming J.P. Morgan Healthcare Conference.

RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference

After reaching an important support level, RxSight, Inc. (RXST) could be a good stock pick from a technical perspective. RXST surpassed resistance at the 50-day moving average, suggesting a short-term bullish trend.

RxSight, Inc. (RXST) Recently Broke Out Above the 50-Day Moving Average

RxSight, Inc. (NASDAQ:RXST ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Alex Huang - Director, Investor Relations Ron Kurtz - President and Chief Executive Officer Shelley Thunen - Chief Financial Officer Conference Call Participants Craig Bijou - Bank of America Larry Biegelsen - Wells Fargo Joseph Conway - Needham & Co Rohin Patel - JPMorgan Steven Lichtman - Oppenheimer Operator Good day, and thank you for standing by. Welcome to the RxSight Third Quarter 2023 Earnings Call.

RxSight, Inc. (RXST) Q3 2023 Earnings Call Transcript

ALISO VIEJO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- November 2, 2023 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced educational opportunities and product updates at the American Academy of Ophthalmology (AAO) Annual Meeting on November 3 – 6 in San Francisco. These include three scientific poster presentations (PO005, PO457, PO050) and 15 booth presentations (booth #229). At these events, leading U.S.-based ophthalmologists are slated to discuss diverse topics, including maximizing clinical results using the Light Adjustable Lens™ (LAL®) across a broad range of patient profiles, integration of the adjustable lens workflow, and real-life case studies showing the impact of high-quality, customized LAL vision. For the full program of events taking place at AAO 2023, click here .

RxSight, Inc. Educational and Product Announcements for AAO 2023

Today we look at RxSight, Inc., a small ocular focused medical device company focused on transforming the cataract surgery market. The company is delivering 70% year-over-year revenue growth and rapidly expanding its installed base. After a big rally early this summer, the stock has given up a third of its value during the overall selloff in the market that began in August.

RxSight: Losing Altitude Despite 'Best Of Breed' Platform

Innodata

IonQ

Invesco S&P SmallCap Information Technology ETF

Rigetti Computing

Small-cap tech stocks have been overshadowed by mega-cap tech giants despite their potential for innovation and future growth. Smaller-cap stocks have appeal for potential acquisition by larger corporations. Three small cap tech stocks focused on AI—Applied Digital (APLD), Innodata (INOD) and Rigetti (RGTI)—are especially intriguing looking ahead into 2024.

Trading The Top-Performing AI Companies From The Small Cap Universe

After reaching an important support level, RxSight, Inc. (RXST) could be a good stock pick from a technical perspective. RXST surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.

RxSight, Inc. (RXST) Crossed Above the 20-Day Moving Average: What That Means for Investors

ALISO VIEJO, Calif., Aug. 23, 2023 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Wells Fargo Healthcare Conference.

RxSight, Inc. to Present at the Wells Fargo Healthcare Conference

RxSight, Inc. (NASDAQ:RXST ) Q2 2023 Earnings Call Transcript August 7, 2023 4:30 PM ET Company Participants Alex Huang - Director, IR Ron Kurtz - President and CEO Shelley Thunen - CFO Conference Call Participants Robbie Marcus - JPMorgan Steven Lichtman - Oppenheimer Ryan Zimmerman - BTIG Craig Bijou - Bank of America David Saxon - Needham & Co Operator Good day and thank you for standing by. Welcome to the RxSight Second Quarter 2023 Earnings Conference Call.

RxSight, Inc. (RXST) Q2 2023 Earnings Call Transcript

RxSight, Inc. (RXST) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.50 per share a year ago.

RxSight, Inc. (RXST) Reports Q2 Loss, Tops Revenue Estimates

ALISO VIEJO, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three and six months ended June 30, 2023.

RxSight, Inc. Reports Second Quarter 2023 Financial Results

ALISO VIEJO, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the second quarter 2023 after the market close on Monday, August 7, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

RxSight, Inc. to Report Second Quarter Financial Results on August 7, 2023

RxSight, Inc. (RXST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in RxSight, Inc. (RXST): Can Its 9.6% Jump Turn into More Strength?

RxSight, Inc. (NASDAQ:RXST ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Alex Huang - Director, IR Ron Kurtz - President and CEO Shelley Thunen - CFO Conference Call Participants Allen Gong - JP Morgan Craig Bijou - Bank of America Joseph Conway - Needham & Co. Ryan Zimmerman - BTIG Steven Lichtman - Oppenheimer Lawrence Biegelsen - Wells Fargo Operator Welcome to the RxSight First Quarter 2023 Earnings Conference Call. Please be advised that today's conference is being recorded.

RxSight, Inc. (RXST) Q1 2023 Earnings Call Transcript

RxSight, Inc. (RXST) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.54 per share a year ago.

RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates

ALISO VIEJO, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2023.

RxSight, Inc. Reports First Quarter 2023 Financial Results

RxSight, Inc. (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will RxSight, Inc. (RXST) Report Negative Earnings Next Week? What You Should Know

ALISO VIEJO, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Bank of America Healthcare Conference.

News for RxSight Stock (RXST)